Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes

A prospective pilot study

Manfredi Rizzo, Nicola Abate, Manisha Chandalia, Ali A. Rizvi, Rosaria V. Giglio, Dragana Nikolic, Antonella Marino Gammazza, Ignazio Barbagallo, Esma R. Isenovic, Maciej Banach, Giuseppe Montalto, Giovanni Li Volti

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Context: Liraglutide is a glucagon-like peptide-1 analog and glucose-lowering agent whose effects on cardiovascular risk markers have not been fully elucidated. Objective: We evaluated the effect of liraglutide on markers of oxidative stress, heme oxygenase-1 (HO-1), and plasma ghrelin levels in patients with type-2 diabetes mellitus (T2DM). Design and Setting: A prospective pilot study of 2 months' duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy. Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; mean age: 57 ± 13y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d) in addition to metformin (1500 mg/d orally) for 2 months. Patients with liver disorders or renal failure were excluded. Main Outcome Measure(s): Plasma ghrelin concentrations, oxidative stress markers, and heat-shock proteins, including HO-1 were assessed. Results: The addition of liraglutide resulted in a significant decrease in glycated hemoglobin (HbA1c) (8.5 ± 0.4 vs 7.5 ± 0.4%, P < .0001). In addition, plasma ghrelin and glutathione concentrations increased (8.2 ± 4.1 vs 13.6 ± 7.3 pg/ml, P = .0007 and 0.36 ± 0.06 vs 0.44 ± 0.07 nmol/ml, P = .0002, respectively), whereas serum lipid hydroperoxides and HO-1 decreased (0.11 ± 0.05 vs 0.04 ± 0.07 pg/ml, P = .0487 and 7.7 ± 7.7 vs 3.6 ± 1.8 pg/ml, P = .0445, respectively). These changes were not correlated with changes in fasting glycemia or HbA1c. Conclusions: In a 2-months prospective pilot study, the addition of liraglutide to metformin resulted in improvement in oxidative stress as well as plasma ghrelin and HO-1 concentrations in patients with T2DM. These findings seemed to be independent of the known effects of liraglutide on glucose metabolism.

Original languageEnglish (US)
Pages (from-to)603-606
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume100
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Heme Oxygenase-1
Ghrelin
Oxidative stress
Medical problems
Type 2 Diabetes Mellitus
Oxidative Stress
Prospective Studies
Plasmas
Metformin
Glucose
Glucagon-Like Peptide 1
Lipid Peroxides
Liver Failure
Glycosylated Hemoglobin A
Heat-Shock Proteins
Metabolism
Liver
Italy
Renal Insufficiency
Glutathione

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes : A prospective pilot study. / Rizzo, Manfredi; Abate, Nicola; Chandalia, Manisha; Rizvi, Ali A.; Giglio, Rosaria V.; Nikolic, Dragana; Gammazza, Antonella Marino; Barbagallo, Ignazio; Isenovic, Esma R.; Banach, Maciej; Montalto, Giuseppe; Volti, Giovanni Li.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 100, No. 2, 01.02.2015, p. 603-606.

Research output: Contribution to journalArticle

Rizzo, M, Abate, N, Chandalia, M, Rizvi, AA, Giglio, RV, Nikolic, D, Gammazza, AM, Barbagallo, I, Isenovic, ER, Banach, M, Montalto, G & Volti, GL 2015, 'Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: A prospective pilot study', Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 2, pp. 603-606. https://doi.org/10.1210/jc.2014-2291
Rizzo, Manfredi ; Abate, Nicola ; Chandalia, Manisha ; Rizvi, Ali A. ; Giglio, Rosaria V. ; Nikolic, Dragana ; Gammazza, Antonella Marino ; Barbagallo, Ignazio ; Isenovic, Esma R. ; Banach, Maciej ; Montalto, Giuseppe ; Volti, Giovanni Li. / Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes : A prospective pilot study. In: Journal of Clinical Endocrinology and Metabolism. 2015 ; Vol. 100, No. 2. pp. 603-606.
@article{97a02c75a44b46b983210a4b2630f9c4,
title = "Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: A prospective pilot study",
abstract = "Context: Liraglutide is a glucagon-like peptide-1 analog and glucose-lowering agent whose effects on cardiovascular risk markers have not been fully elucidated. Objective: We evaluated the effect of liraglutide on markers of oxidative stress, heme oxygenase-1 (HO-1), and plasma ghrelin levels in patients with type-2 diabetes mellitus (T2DM). Design and Setting: A prospective pilot study of 2 months' duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy. Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; mean age: 57 ± 13y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d) in addition to metformin (1500 mg/d orally) for 2 months. Patients with liver disorders or renal failure were excluded. Main Outcome Measure(s): Plasma ghrelin concentrations, oxidative stress markers, and heat-shock proteins, including HO-1 were assessed. Results: The addition of liraglutide resulted in a significant decrease in glycated hemoglobin (HbA1c) (8.5 ± 0.4 vs 7.5 ± 0.4{\%}, P < .0001). In addition, plasma ghrelin and glutathione concentrations increased (8.2 ± 4.1 vs 13.6 ± 7.3 pg/ml, P = .0007 and 0.36 ± 0.06 vs 0.44 ± 0.07 nmol/ml, P = .0002, respectively), whereas serum lipid hydroperoxides and HO-1 decreased (0.11 ± 0.05 vs 0.04 ± 0.07 pg/ml, P = .0487 and 7.7 ± 7.7 vs 3.6 ± 1.8 pg/ml, P = .0445, respectively). These changes were not correlated with changes in fasting glycemia or HbA1c. Conclusions: In a 2-months prospective pilot study, the addition of liraglutide to metformin resulted in improvement in oxidative stress as well as plasma ghrelin and HO-1 concentrations in patients with T2DM. These findings seemed to be independent of the known effects of liraglutide on glucose metabolism.",
author = "Manfredi Rizzo and Nicola Abate and Manisha Chandalia and Rizvi, {Ali A.} and Giglio, {Rosaria V.} and Dragana Nikolic and Gammazza, {Antonella Marino} and Ignazio Barbagallo and Isenovic, {Esma R.} and Maciej Banach and Giuseppe Montalto and Volti, {Giovanni Li}",
year = "2015",
month = "2",
day = "1",
doi = "10.1210/jc.2014-2291",
language = "English (US)",
volume = "100",
pages = "603--606",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes

T2 - A prospective pilot study

AU - Rizzo, Manfredi

AU - Abate, Nicola

AU - Chandalia, Manisha

AU - Rizvi, Ali A.

AU - Giglio, Rosaria V.

AU - Nikolic, Dragana

AU - Gammazza, Antonella Marino

AU - Barbagallo, Ignazio

AU - Isenovic, Esma R.

AU - Banach, Maciej

AU - Montalto, Giuseppe

AU - Volti, Giovanni Li

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Context: Liraglutide is a glucagon-like peptide-1 analog and glucose-lowering agent whose effects on cardiovascular risk markers have not been fully elucidated. Objective: We evaluated the effect of liraglutide on markers of oxidative stress, heme oxygenase-1 (HO-1), and plasma ghrelin levels in patients with type-2 diabetes mellitus (T2DM). Design and Setting: A prospective pilot study of 2 months' duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy. Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; mean age: 57 ± 13y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d) in addition to metformin (1500 mg/d orally) for 2 months. Patients with liver disorders or renal failure were excluded. Main Outcome Measure(s): Plasma ghrelin concentrations, oxidative stress markers, and heat-shock proteins, including HO-1 were assessed. Results: The addition of liraglutide resulted in a significant decrease in glycated hemoglobin (HbA1c) (8.5 ± 0.4 vs 7.5 ± 0.4%, P < .0001). In addition, plasma ghrelin and glutathione concentrations increased (8.2 ± 4.1 vs 13.6 ± 7.3 pg/ml, P = .0007 and 0.36 ± 0.06 vs 0.44 ± 0.07 nmol/ml, P = .0002, respectively), whereas serum lipid hydroperoxides and HO-1 decreased (0.11 ± 0.05 vs 0.04 ± 0.07 pg/ml, P = .0487 and 7.7 ± 7.7 vs 3.6 ± 1.8 pg/ml, P = .0445, respectively). These changes were not correlated with changes in fasting glycemia or HbA1c. Conclusions: In a 2-months prospective pilot study, the addition of liraglutide to metformin resulted in improvement in oxidative stress as well as plasma ghrelin and HO-1 concentrations in patients with T2DM. These findings seemed to be independent of the known effects of liraglutide on glucose metabolism.

AB - Context: Liraglutide is a glucagon-like peptide-1 analog and glucose-lowering agent whose effects on cardiovascular risk markers have not been fully elucidated. Objective: We evaluated the effect of liraglutide on markers of oxidative stress, heme oxygenase-1 (HO-1), and plasma ghrelin levels in patients with type-2 diabetes mellitus (T2DM). Design and Setting: A prospective pilot study of 2 months' duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy. Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; mean age: 57 ± 13y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d) in addition to metformin (1500 mg/d orally) for 2 months. Patients with liver disorders or renal failure were excluded. Main Outcome Measure(s): Plasma ghrelin concentrations, oxidative stress markers, and heat-shock proteins, including HO-1 were assessed. Results: The addition of liraglutide resulted in a significant decrease in glycated hemoglobin (HbA1c) (8.5 ± 0.4 vs 7.5 ± 0.4%, P < .0001). In addition, plasma ghrelin and glutathione concentrations increased (8.2 ± 4.1 vs 13.6 ± 7.3 pg/ml, P = .0007 and 0.36 ± 0.06 vs 0.44 ± 0.07 nmol/ml, P = .0002, respectively), whereas serum lipid hydroperoxides and HO-1 decreased (0.11 ± 0.05 vs 0.04 ± 0.07 pg/ml, P = .0487 and 7.7 ± 7.7 vs 3.6 ± 1.8 pg/ml, P = .0445, respectively). These changes were not correlated with changes in fasting glycemia or HbA1c. Conclusions: In a 2-months prospective pilot study, the addition of liraglutide to metformin resulted in improvement in oxidative stress as well as plasma ghrelin and HO-1 concentrations in patients with T2DM. These findings seemed to be independent of the known effects of liraglutide on glucose metabolism.

UR - http://www.scopus.com/inward/record.url?scp=84922569481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922569481&partnerID=8YFLogxK

U2 - 10.1210/jc.2014-2291

DO - 10.1210/jc.2014-2291

M3 - Article

VL - 100

SP - 603

EP - 606

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -